This summary was created by AI, based on 3 opinions in the last 12 months.
Agios Pharmaceuticals Inc. (AGIO) has received mixed reviews from experts regarding its investment potential. Following a decline in stock price, one expert has recommended covering a previous position due to a loss of 19.8%. However, another analyst continues to endorse the company, highlighting its promising pipeline of cancer treatment products expected to become commercial in the upcoming year, with strong potential for cash flow growth. AGIO's trading metrics show it at 3x earnings and 1.2x book value, alongside a notable ROE of 57%. Recommendations include setting stop-loss measures while aiming for price increases, reflecting a belief in its upside potential despite recent market performance. Analysts' price targets suggest potential for significant gains, reinforcing the company's favorable outlook in the biopharma sector.
Agios Pharmaceuticals Inc. is a American stock, trading under the symbol AGIO-Q on the NASDAQ (AGIO). It is usually referred to as NASDAQ:AGIO or AGIO-Q
In the last year, 1 stock analyst published opinions about AGIO-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Agios Pharmaceuticals Inc..
Agios Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Agios Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Agios Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-11, Agios Pharmaceuticals Inc. (AGIO-Q) stock closed at a price of $26.7.
Our PAST TOP PICK with AGIO has triggered its stop at $25. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 23%, when combined with our previous guidance.